Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
0.2644
-0.0288 (-9.82%)
At close: Apr 4, 2025, 4:00 PM
0.2647
+0.0003 (0.13%)
After-hours: Apr 4, 2025, 7:50 PM EDT

Cellectar Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-44.58-42.77-31.79-24.12-15.09
Upgrade
Depreciation & Amortization
0.290.190.150.150.14
Upgrade
Loss (Gain) From Sale of Assets
0.15-00-
Upgrade
Stock-Based Compensation
4.272.411.451.120.47
Upgrade
Other Operating Activities
-5.994.323.280.08-0.12
Upgrade
Change in Accounts Payable
-1.593.71.620.410.78
Upgrade
Change in Other Net Operating Assets
-0.13-0.220.06-0.21-0.11
Upgrade
Operating Cash Flow
-47.58-32.38-25.22-22.57-13.93
Upgrade
Capital Expenditures
-0.1-0.86-0.23-0.14-0.06
Upgrade
Investing Cash Flow
-0.1-0.86-0.23-0.14-0.06
Upgrade
Long-Term Debt Issued
----0.18
Upgrade
Total Debt Issued
----0.18
Upgrade
Net Debt Issued (Repaid)
----0.18
Upgrade
Issuance of Common Stock
61.4122.949.611.2560.36
Upgrade
Financing Cash Flow
61.4122.949.611.2560.55
Upgrade
Net Cash Flow
13.72-10.3-15.84-21.4646.55
Upgrade
Free Cash Flow
-47.69-33.24-25.45-22.71-14
Upgrade
Free Cash Flow Per Share
-1.28-2.72-3.61-4.09-7.06
Upgrade
Cash Interest Paid
----0
Upgrade
Levered Free Cash Flow
-43.97-8.99-8.83-13.63-8.23
Upgrade
Unlevered Free Cash Flow
-43.97-8.99-8.83-13.63-8.23
Upgrade
Change in Net Working Capital
16.07-13.62-7.8-0.32-0.78
Upgrade
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q